Assessing lymphoma treatment response using advanced DNA analysis
Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing
National Taiwan University Hospital · NCT06550427
This study is testing if analyzing DNA from blood can help doctors see how well treatment is working for patients with aggressive B-cell lymphoma without using radiation from scans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital (other) |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06550427 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on evaluating the treatment response in patients with aggressive B-cell lymphoma through the analysis of circulating tumor DNA (ctDNA) using phased variant analysis and next-generation sequencing (NGS). The study aims to provide a safer alternative to traditional imaging methods like CT and PET scans, which involve radiation exposure. By analyzing ctDNA, researchers hope to gain insights into the molecular characteristics of the tumor and the patient's clinical status, potentially leading to more accurate early assessments of treatment efficacy.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with pathology-proven aggressive B-cell lymphoma.
Not a fit: Patients with non-aggressive forms of lymphoma or those under 18 years old may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to safer and more effective monitoring of lymphoma treatment responses, improving patient outcomes.
How similar studies have performed: While the use of ctDNA analysis is gaining traction, this specific approach using phased variant analysis in lymphoma treatment response assessment is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Pathology proven lymphoma * Age ≥ 18 years old Exclusion Criteria: * none
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (RECRUITING)
Study contacts
- Principal investigator: Tai-Chung Huang, Ph.D — National Taiwan University Hospital
- Study coordinator: Tai-Chung Huang, Ph.D
- Email: tch01@ntu.edu.tw
- Phone: +886-972-651392
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lymphoma, Hodgkin Lymphoma, T-cell Lymphoma, Waldenstrom Macroglobulinaemia, NGS, Phased Variant, Early Response Assessment, Early Outcome